A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies

"A single infusion of ONCT-808 autologous CAR-T cell infusion will be administered intravenously~Phase 1: Dose Escalation with bridging therapy as needed~Phase 2: Patients with LBCL or MCL will be enrolled into two separate dose expansion cohorts."

Bridging therapy can be oral chemotherapy or IV radiotherapy/chemotherapy per institution's guidelines